Another day, another chance for Eli Lilly to prove it is more than just a leader in weight-loss drugs. That validation came in the form of a regulatory win for its experimental cancer treatment, olomorasib.

The Food and Drug Administration on Monday granted olomorasib orphan drug designation. The status is reserved for investigational treatments that target rare, life-threatening diseases affecting fewer than 200,000 people in the U.S.

The move also builds on a decision by the FDA in August, which granted olomorasib Breakthrough Therapy status as a standalone treatment for adults with a specific form of pancreatic cancer who have received at least one prior therapy.

The oral drug targets KRAS G12C, a mutated protein that drives cancer cells to multiply. It is currently being evaluated across several advanced solid tumors, including non-small cell lung cancer and pancreatic cancer.

While the latest development doesn't approve olomorasib for sale or advance the drug to a new phase of clinical testing, it nevertheless represents a milestone. For Lilly, the designation validates its push to expand its oncology footprint while unlocking substantial financial and regulatory incentives. Crucially, orphan status grants seven years of market exclusivity following FDA approval.

It also brings olomorasib one step closer to patients by keeping it on regulators' radar. Roughly 66,000 people in the U.S. are diagnosed with pancreatic cancer each year, with an estimated 50,000 deaths projected annually.

In August, Lilly highlighted growing evidence that patients with KRAS G12C-mutant pancreatic cancer face worse outcomes than those lacking the mutation. There are no currently approved, targeted therapies that address this form of the disease.